
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab is well-positioned for future growth in the biotechnology sector due to its track record of profitability, strong balance sheet, solid positioning in multiple myeloma treatment with DARZALEX, and a broad pipeline with potential for numerous clinical data catalysts. They use a discounted cash flow approach to value the company and have assigned a 12-month price objective of $39 per share, with a 100% probability of approval for DARZALEX and other high probabilities for pipeline candidates targeting various oncologic indications. Risks include potential slowing of DARZALEX sales, failure to obtain label extensions for DARZALEX, and negative results from EPKINLY trials, among other risks.
Bears say
Genmab is heavily reliant on DARZALEX, their leading
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares